Carcinoid Syndrome
Conditions
Brief summary
Serotonin has recently been identified as a major regulator of bone formation. Gut-derived serotonin inhibits bone formation, and early animal studies have shown that inhibition of gut-derived serotonin has anabolic effects on bone in ovariectomised rodents. This pathway has potential to be developed as a new anabolic treatment for osteoporosis in humans. Carcinoid neuro-endocrine tumours produce very high levels of serotonin, and so it might be expected that patients with carcinoid disease would have reduced bone formation, low bone mass and fractures. However, this has not been apparent in clinical practice. There may be a discrepancy between rodent models and human disease. This study aims to identify whether patients with carcinoid disease have reduced bone mass, reduced bone formation or high fracture rates. The investigators will conduct a cross-sectional observational case-control study of patients with carcinoid disease in the Sheffield neuro-endocrine tumour clinic and gender-, age- and body mass index (BMI)-matched controls.
Interventions
None listed
Sponsors
University of Sheffield
Sheffield Teaching Hospitals NHS Foundation Trust
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Willing to participate * Able to give informed consent * Patient with carcinoid syndrome-active disease (untreated or receiving medical treatment) * or * Healthy volunteer who adequately matches a patient with carcinoid syndrome gender, age (±5 years), height (±5cm) and BMI(±3 kg/m2)
Exclusion criteria
* Curative surgery for carcinoid disease * Body weight over 159 kg (weight limit for DXA measurement of BMD) * Previous orthopaedic surgery or fractures which preclude imaging at all sites * History of any long term immobilization (duration greater than three months) * Fracture less than one year prior to recruitment * Current pregnancy or trying to conceive * Delivery of last child less than one year prior to recruitment * Breast feeding less than one year prior to recruitment * History of, or current conditions known to affect bone metabolism * Diagnosed skeletal disease or inflammatory arthritis * Chronic renal disease * Malabsorption syndromes * Other diagnosed endocrine disorders * Hypocalcemia or hypercalcemia * Diagnosed restrictive eating disorder * Diabetes mellitus * Conditions or surgery which prevent the acquisition or analysis of DXA, VFA or HR-pQCT * Use of medications or treatment known to affect bone metabolism * Alcohol intake greater than 21 units per week
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lumbar spine and total hip Bone Mineral Density BMD) measured by Dual-emission X-ray absorptiometry (DXA) | — |
Secondary
| Measure | Time frame |
|---|---|
| Vertebral fracture assessment | — |
| Radius and tibia geometry and microarchitecture by HR-pQCT | — |
| Serum osteocalcin | — |
| Blood serotonin and 5HIAA | — |
| Self-reported fracture history | — |
| Serum type 1 procollagen (N-terminal)(PINP) | — |
| Bone Alkaline Phosphatase (BAP) | — |
| Carboxy-terminal collagen crosslinks (CTX) | — |
| 24h urine 5HIAA | 24 hours |
Countries
United Kingdom
Outcome results
None listed